Clinical trials - HealthQuill

GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

GSK to pay Chimagen $300m upfront to develop autoimmune drug

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

by HealthQuill
October 30, 2024
0 Comments

Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.

Drugs Health Pharma

Novartis to pay Monte Rosa $150m upfront for MGD drug candidates

Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise.

by HealthQuill
October 28, 2024
0 Comments

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy medicine in a trial, according to a statement.

Drugs Health Pharma

Novo’s type 2 oral diabetic drug cuts heart diseases by 14% in a trial

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.

by HealthQuill
October 21, 2024
0 Comments

Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.

Drugs Health Pharma

Astellas Pharma gets US regulator’s nod for its gastric cancer drug

Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.

by HealthQuill
October 21, 2024
0 Comments

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to extend the lives of patients who had undergone prior treatments.

Drugs Health Pharma

Gilead’s end-stage confirmatory trials of bladder cancer drug fail

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.

by HealthQuill
October 21, 2024
0 Comments

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.

Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

by HealthQuill
October 20, 2024
0 Comments

Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the US regulator after a volunteer developed a serious nerve disorder.

Drugs Medical Pharma

USFDA puts on hold influenza, Covid-19 trial vaccines of Novavax

Novavax, Inc.’s mid-stage trials on a combination of Covid-19 and influenza and a standalone influenza vaccine have been put on hold by the.

by HealthQuill
October 17, 2024
0 Comments

Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder in haemophilia patients.

Drugs Health Pharma

Pfizer’s drug to treat rare haemophilia disorder gets US regulator’s approval

Pfizer Inc., got a nod from the US drug regulator for its drug Hympavzi to treat two types of a rare blood disorder.

by HealthQuill
October 13, 2024
0 Comments

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered company has halted its trials.

Drugs Health Pharma

Sage Therapeutics halts trials of experimental drug to treat dementia

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.